{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000078","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.026884+00:00","generated_at":"2026-05-31T00:46:04.674196+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Keros completes Phase 2 PAH trial TROPOS enrollment with 113 patients; topline Q2 2025","bullets":["Completed enrollment of TROPOS Phase 2 trial of cibotercept (KER-012) for pulmonary arterial hypertension.","Enrolled 113 patients, exceeding the initial target of 90 patients.","Topline data expected to be presented in the second quarter of 2025.","Trial evaluates cibotercept in combination with background therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000078","json":"https://secwatch.observer/filing/0001664710-24-000078.json","markdown":"https://secwatch.observer/filing/0001664710-24-000078.md","text":"https://secwatch.observer/filing/0001664710-24-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000078/0001664710-24-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000078/kros-20240930.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T00:46:04.674196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}